Clinical Trials on BRCA-Associated Breast Carcinoma in United Kingdom

Total 1278 results

Royal Marsden NHS Foundation Trust

Completed

Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer (MR-BTC)

MRI | BRCA1 Mutation | BRCA2 Mutation | Mammography

United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Breast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation

United States
Tango Therapeutics, Inc.

Terminated

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | BRCA1 Mutation | BRCA-Mutated Ovarian Carcinoma | BRCA-Associated Breast Carcinoma | HRD Positive Advanced Ovarian Cancer

United States
NYU Langone Health

Withdrawn

3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women

Breast Cancer | BRCA1 Mutation | BRCA2 Mutation

United States
Weill Medical College of Cornell University

Completed

Web-based Family History Tool (Progeny)

Breast Cancer | Gynecologic Cancer | BRCA1 Mutation | BRCA2 Mutation

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Breast Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

Breast Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
Steven J Isakoff, MD, PhD
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Abbott

Active, not recruiting

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Breast Cancer | Metastatic Breast Cancer | BRCA1 Gene Mutation | brca2 Gene Mutation

United States
University of Southern California
National Cancer Institute (NCI); California Breast Cancer Research Program

Completed

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Lobular Breast Carcinoma in Situ

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Stage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
Abramson Cancer Center at Penn Medicine

Active, not recruiting

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast Cancer

United States
University College London Hospitals

Completed

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | brca1 Mutation Carrier | brca2 Mutation Carrier

Australia, Israel, United Kingdom, Spain, Sweden, Portugal
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Breast Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
University of Washington
National Cancer Institute (NCI); National Institute of Nursing Research (NINR)

Completed

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer (DEEM)

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ | Atypical Lobular Breast Hyperplasia

United States
Ohio State University Comprehensive Cancer Center

Completed

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Ductal Breast Carcinoma in Situ | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
Georgetown University

Completed

The Genetic Education for Men Trial: Web-Based Education vs. Standard Care (GEM)

Pancreatic Cancer | Breast Neoplasm | BRCA1 Mutation | BRCA2 Mutation | Prostate Carcinoma

United States
Massachusetts General Hospital

Completed

Depression and Body Image Distress Following Mastectomy With Reconstruction

Breast Cancer | BRCA1 Mutation | BRCA2 Mutation

United States
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7 | Metastatic Breast Carcinoma | Metastatic BRCA-Associated Breast Carcinoma

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

BRCA1 Syndrome | BRCA2 Syndrome | No Evidence of Disease | Hereditary Ovarian Carcinoma | Hereditary Female Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

Obesity | Overweight | Ductal Breast Carcinoma In Situ | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Premalignant Lesion

United States
University of Washington
GlaxoSmithKline

Recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic... and other conditions

United States
Cancer Research UK

Completed

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Breast Cancer | Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United Kingdom
Pfizer
Medivation, Inc.; Myriad Genetic Laboratories, Inc.

Terminated

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) (ABRAZO)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

United States, Spain, United Kingdom, Germany, France
University of Washington
AbbVie

No longer available

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Triple-Negative Breast Cancer | Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditions

United States
University of Texas Southwestern Medical Center

Completed

Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM) (SPrNSM)

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditions

United States
Dana-Farber Cancer Institute
Johns Hopkins University; GlaxoSmithKline; Translational Breast Cancer Research...

Recruiting

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer | Deleterious PALB2 Gene Mutation | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation

United States
Columbia University
American Cancer Society, Inc.

Completed

Decision Support for BRCA Testing in Ethnically Diverse Women

Breast Cancer | Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation

United States
Mayo Clinic
Allergan

Completed

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

Neoplasms | Pain, Postoperative | Breast Cancer | Breast Diseases | BRCA1 Mutation | BRCA2 Mutation

United States
Northwestern University
Northwestern Memorial Hospital; Saint Joseph Hospital, Chicago, Illinois

Recruiting

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage

Breast Cancer | BRCA Mutation

United States
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Austrian Breast & Colorectal Cancer Study...

Recruiting

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P)

Neoplasms | Breast Cancer | Breast Neoplasms | Breast Diseases | Breast Carcinoma | BRCA1 Mutation

United States
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
National Cancer Institute (NCI)

Completed

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Familial Ovarian Cancer | Familial Breast Cancer | BRCA1-associate Malignancies | BRCA2-associated Malignancies

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
University College, London

Unknown

TARGeted Intraoperative radioTherapy (TARGIT) Registry Database (TARGIT R)

Early-Stage Breast Carcinoma

United Kingdom
Uppsala University
Royal Marsden NHS Foundation Trust; Uppsala University Hospital; Westmead Breast... and other collaborators

Recruiting

Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value) (OncoPROValue-1)

Breast Cancer | Breast Carcinoma in Situ | Breast Cancer Invasive | Breast Asymmetry

United Kingdom, Sweden, Australia
Beth Israel Deaconess Medical Center
Johns Hopkins University; Dana-Farber Cancer Institute; AstraZeneca

Active, not recruiting

Olaparib In Metastatic Breast Cancer

Metastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)

United States
The National Institute of Lymphology
The DrMarga Practice Group; The Center for Restorative Breast Surgery, LLC

Unknown

Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Congenital Lymphedema | Acquired Lymphedema

United States
General Oncology, Inc.
Myriad Genetics, Inc.

Recruiting

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditions

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Genetics and Heart Health After Cancer Therapy (Gene-HEART)

Heart Diseases | Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Drug-Induced Cardiomyopathy

United States
Pamela Munster
QuantumLeap Healthcare Collaborative

Terminated

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Triple Negative Metastatic Breast Cancer | BRCA-mutated Solid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions

United States
858 Therapeutics, Inc.

Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Advanced or Metastatic Solid Tumors | ER+ Breast Cancer | Castrate Resistant Prostate Cancer | BRCA Mutation

United States
University College, London
European Union

Completed

PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional (PICTURE XS)

Early-Stage Breast Carcinoma

United Kingdom, Netherlands, Portugal
University of Washington
National Cancer Institute (NCI)

Completed

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer | Hereditary Breast/Ovarian Cancer - BRCA1 | Hereditary Breast/Ovarian Cancer...

United States

Clinical Trials on BRCA-Associated Breast Carcinoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations